PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey

Similar documents
Late complications after hematopoietic stem cell transplant in adult patients

Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life

Late effects after HSCT

4nd Patient and Family Day

Reduced-intensity Conditioning Transplantation

HCT for Myelofibrosis

EBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation

Donatore HLA identico di anni o MUD giovane?

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients

Stem cell transplantation in elderly, but fit multiple myeloma patients

Workshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

AML:Transplant or ChemoTherapy?

AIH, Marseille 30/09/06

SKIN CANCER AFTER HSCT

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Outcome of patients with hematologic malignancy admitted to the ICU

Survivorship After Stem Cell Transplantation and Long-term Followup

Protecting Your Health After Transplant (Adults)

Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor

Haploidentical Transplantation today: and the alternatives

Should patients with higher risk MDS (or AML in «early relapse») proceed directly to allo SCT without prior chemotherapy?

Dr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.

ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda

Stem cell Survivorship: Searching for a solution to our success. Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic

Outline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Late effects, health status and quality of life after hemopoietic stem cell

Brentuximab, Nivolumab: L esperienza Real Word della REP. Dr.ssa Clara De Risi Az. Osp. Card. G. Panico - Tricase

Corporate Medical Policy

Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham

COHEM Barcellona 2012 Hemoglobinopathies debate

Psychosocial Late Effects. of Childhood Cancer. Matt Bitsko, Ph.D Departments of Pediatrics and Psychology

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK

Checkpoint Blockade in Hematology and Stem Cell Transplantation

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints

An Introduction to Bone Marrow Transplant

ASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS

Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center

Haploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy

Comparing outcome between Belgian haematopoietic stem cell transplant centres

Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology

An Overview of Blood and Marrow Transplantation

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017

The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014

Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -

Allogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra

Late Effects of Transplants: Lessons learned and strategies to improve the health of the HCT survivor

Bone Marrow Transplantation and the Potential Role of Iomab-B

Late Complications. Objectives. Long-term Survival after HCT. Long-term Survival and Late Complications after HCT. Long-term Survival after HCT

Late Complications. Navneet Majhail, MD, MS

Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist

Late effects and long-term survivorship after HSCT

Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE

Which is the best treatment for relapsed APL?

Disclosures of: Emanuele Angelucci

Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials

THE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore

Late Effects after Transplantation for Pediatric Severe Aplastic Anemia. Jean E. Sanders, M.D.

Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Abstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ

Long-Term Outcomes After Hematopoietic Cell Transplantation

Il Trapianto da donatore MUD. Alessandro Rambaldi

Blood & Marrow Transplantation Center

Disclosure. Objectives 1/22/2015

What s a Transplant? What s not?

Late effects and quality of life after haematological stem cell transplantation

State of the Art Treatment for Relapsed Mantle Cell Lymphoma

Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years

Stem Cell Transplantation for Severe Aplastic Anemia

EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016

"Chemotherapy based stem cell mobilization: pro and con"

Disclosures. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.

Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Corporate Medical Policy

Summary. Ladislav Slovacek 1,2 ABCDE, Birgita Slovackova 3 ABCD, Vladimir Pavlik 4 DEFG, Ladislav Jebavy 1,5 DEFG

options in Myeloablative HSCT

ADVANCES IN THE MANAGEMENT OF MYELODYSPLASTIC SYNDROMES

Induction Therapy & Stem Cell Transplantation for Myeloma

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Getting Fit for Transplant. Thuy Koll, MD Assistant Professor Division of Geriatrics Department of Internal Medicine

Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT

THE LEUKEMIAS. Etiology:

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

Transcription:

PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey Joint Educational Meeting of the EBMT Severe Aplastic Anaemia, Late Effects and Autoimmune Diseases Working Parties 3rd - 6th November 2011, Barcelona, Spain

Flow Components of QoL Health related QoL Performance after Allo HSCT (BMT-SS) Children Performance after AutoHSCT Intervention? Possible How to run a study? Take home messages, future, general summary

Components of QoL Global QoL Physical (Fatigue, Pain) Emotional (Anxiety, Depression) Social (Family, friends) Functional (Work, sleep) Spiritual (religion, meaning) in HSCT, SJ Lee, QoL issues post tx., 537-51

HRQoL: rısk factors changes according tıme Bevans, ASH Ed. Book, 2010

performance after allo hsct

Impact of different post-remission strategies on QoL in patients with AML German AML-Intergroup, survey on QoL with a RFS> 5 years after 1st Tr 419 of 818 patients (51.2%) median age: 42 years, and the med. f/u: 8 years EORTC QoL C30 121 allohct, 49 autohct in CR1; 249 CCT Haematologica 2008; 93: 826-833.

Impact of different post-remission strategies on QoL in patients with AML German AML-Intergroup, survey on QoL with a RFS> 5 years after 1st Tr 419 of 818 patients (51.2%) median age: 42 years, and the med. f/u: 8 years EORTC QoL C30 121 allohct, 49 autohct in CR1; 249 CCT Haematologica 2008; 93: 826-833.

Impact of different post-remission strategies on QoL in patients with AML Haematologica 2008; 93: 826-833.

Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease Bone Marrow Transplant. 2010; 45: 762 769

Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease N=100, allo HSCT. Utility of three instruments recommended by the NIH; SF-36, the distance walked in 2 min, Lee chronic GVHD symptom bother scale. Results: Functional performance, measured by the SF-36 physical component summary score, was substantially lower (mean = 36.8±10.7) than the US population norm of 50 (P<0.001). The most severe decrements were in physical function (mean = 38.8±10.9) and physical role function (mean= 37.88±11.88) Bone Marrow Transplant. 2010; 45: 762 769

Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease Bone Marrow Transplant. 2010; 45: 762 769

bone marrow transplant survivor study (bmt-ss) A collaboration between City of Hope Cancer Center (and the University of Minnesota, established in 2000 Aim: To evaluate outcomes in a cohort of individuals with a diagnosis of cancer or other life-threatening illness Eligibility criteria: 1. HCT for hematologic and non-hematologic malignancies and other life-threatening disorders; 2. Date of transplantation between 01/1974-12/1998 3. Survival of 2 years or longer after HCT regardless of disease and SCT PIs: S. Bathia, D. Weisdorf Publications: 17 papers, since 2004

Impact of cgvhd on the health status of hematopoietic cell transplantation survivors: a report from the BMT-SS N=584 Blood. 2006;108: 2867-2873

Impact of cgvhd on the health status survivors: a report from the BMT-SS

functional status of long-term survivors: BMT-SS N=1479, >2 years post allohct. Med. age: 25.9 y Median f/u: 9.5 y. HCT survivors difficulty in holding jobs ([OR] 13.9) in obtaining health (OR: 7.1) or life (OR: 9.9) insurance compared with siblings (N=319) Blood. 2007;110:3784-3792

Letter: very long-term survivors after HSCT Basel Group N=44, paired controls. f/u: 17.5 y physical health status can be impaired, while mental health preserved Blood. 2008;111:1740

Functional status limitations among survivors, overall and by diagnosis, compared to siblings: BMT-SS N= 401 (AML/ALL), siblings of participants (n=319) are controls Med age: 36.5 yr survivors/ 44yr siblings. Med. f/u: 8.4 yr. Conditioning included TBI in 86% of AML and 100% of ALL subjects. Compared to siblings, survivors had a higher frequency of exercise induced shortness of breath (DOI), neurosensory impairments, and problems with balance, tremor or weakness. M-V analysis, the risk did not differ by diagnosis. Abnormal sense of touch (OR 2.6, p=0.02) and to report their overall health as fair or poor (OR 2.2, p=0.03). (OP x3, DM x4) Conclusion: Ongoing surveillance for LEs and appropriate interventions are required to improve the health Leukemia. 2010; 24: 2039 2047

functional status limitations among survivors, overall and by diagnosis, compared to siblings: BMT-SS Leukemia. 2010; 24: 2039 2047

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS N=1065 (69%) 56% Allo HCT Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS presence of active chronic GVHD were associated with a 2-fold increased risk for somatic distress. 7% of the HCT survivors expressed suicidal ideation; patients with higher scores on depression subscale were most vulnerable Somatic distress is the biggest challenge Blood. 2011;118: 4723-4731

Adverse psychological outcomes in long-term survivors of HCT: BMT-SS presence of active chronic GVHD were associated with a 2-fold increased risk for somatic distress. 7% of the HCT survivors expressed suicidal ideation; patients with higher scores on depression subscale were most vulnerable Somatic distress is the biggest challenge Blood. 2011;118: 4723-4731

Chıldren

Performance Limitations and Participation Restrictions Among Childhood Cancer Survivors Treated With HCT

Performance Limitations and Participation Restrictions Among Childhood Cancer Survivors Treated With HCT N=235 age<21, alive >2 years, BMT-SS Arch Pediatr Adolesc Med. 2005;159:706-713

performance after Auto HSCT&HDCT

Quality of life and rehabilitation in social and professional life after AHSCT&HDCT C-S, n=391, 12 y.s, 78% ASCT: significant, unfavourable impact on QoL (reintegration into social and professional life). Most symptoms and scores returned to N 3-6 years. Employment status and QoL were similar in patients who participated or not Annals of Oncology 13: 209 217, 2002

ıs Intervention possıble?

A randomized trial on the effect of a multimodal intervention on physical capacity, functional performance and QoL in adult patients undergoing allosct Randomized controlled trial Aim: investigate the effect of a 4- to 6-week multimodal program of exercise, relaxation and psychoeducation Physical capacity, Functional performance and QoL in allo-hsct N=42, adult pat.s 1st end point: aerobic capacity measured in VO2 max. 2nd end points: muscle strength, functional performance, physical activity level, QoL, fatigue, psychological wellbeing and clinical outcomes. Bone Marrow Transplantation (2009) 43, 725 737

A randomized trial on the effect of a multimodal intervention on physical capacity, functional performance and quality of life in adult patients Table 1 Multimodal intervention: exercise, progressive relaxation and psychoeducation Mode Frequency Intensity Duration Progression Stationary cycling 5 days/week Low to moderate: 50 75% HR max, RPE 10 13, MET 5.5 15 30 min/session rest intervals as needed Dynamic and 5 days/week Dynamic: 1 2 sets, 10 12 reps 15 20 min/session stretching exercises Static: 1 set, hold for 15 30 s MET 3.5 Resistance training 3 days/week Low to moderate: 1 2 sets of 10 12 reps, 15 20 min/session RPE 10 13, MET 3 Progressive relaxation 2 days/week Low: RPE 6 9, MET 2.5 20 min/session Psychoeducation Ongoing Increased intensity and duration ¼ ¼ ¼ ¼ Bone Marrow Transplantation (2009) 43, 725 737

Intervention: possıble! Multimodal Intervention with aerobic, resistance and active exercises, progressive relaxation and psychoeducation; sustained 1- aerobic fitness, 2- muscle strength and 3- minimized loss of functional performance, favored the intervention group, but did not reach statistical significance. no untoward events sustained aerobic capacity and muscle strenght reduced loss of functional performance Bone Marrow Transplantation (2009) 43, 725 737

AIM: Effectiveness of an individualized high intensity strength and interval training program with respect to physiological and psychological health status PATs: MM & NHL, ASCT&HDCT, N=120, incl.period 2 y. METHODs: Multicenter, prospective, single blind randomized controlled trial will be performed. (1) intervention plus usual care; or (2) usual care. The intervention consists of an18-week individualized supervised high-intensity exercise program and counselling. The primary outcomes: cardiorespiratory fitness, muscle strength and fatigue) and secondary outcomes are assessed at BL, completion of the intervention and at 12 mo.s BMC Cancer 2010, 10:671

How to run a study?

Function, Adjustment, Quality of Life and Symptoms (FAQS) in Allo HSCT Survivors: A Study Protocol Aim: 1. explore the patterns of change in these health outcomes during the survivorship phase 2. characterize subgroups of survivors experiencing adverse outcomes 3. Examine relationships among outcomes and demographic 4. clinical factors (such as age, graft-versus-host disease (GVHD), and disease relapse) Health and Quality of Life Outcomes 2011, 9:24

Function, Adjustment, Quality of Life and Symptoms (FAQS) in Allo HSCT Survivors: A Study Protocol Methodology: Longitudinal observational study, adults, who >3 y post Allo HSCT, Qs annually. Demographic and clinical data with a series of patient-reported outcome measures, specifically: 1) Medical Outcomes Study SF- 36; 2) Functional Assessment of Chronic Illness Therapy (FACIT) - General 3) FACIT-Fatigue; 4) FACIT- Spiritual; 5) Psychosocial Adjustment to Illness Scale; 6) Rotterdam Symptom Checklist-Revised 7) Pittsburgh Sleep Quality Index. Health and Quality of Life Outcomes 2011, 9:24

Sample: fact-g /vrs. 4)

Current status conclusıon future prospects last words

Chronic Health Condıtıons

Health Care Utilization by Adult Long-term Survivors of HCT : BMT-SS Report HCU: general contact with health care system, general physical examination, and cancer/hct related visit N=845, f/u: 6 ys. Conclusion: need for increased awareness of the LT f/u needs of the HCT survivors by the health care providers Cancer Epidemiol Biomarkers Prev 2007;16: 834 9

Health Care Utilization by Adult Long-term Survivors of HCT : BMT-SS Report HCU: general contact with health care system, general physical examination, and cancer/hct related visit N=845, f/u: 6 ys. Conclusion: need for increased awareness of the LT f/u needs of the HCT survivors by the health care providers Cancer Epidemiol Biomarkers Prev 2007;16: 834 9

Current STATUS on QoL related performance Bevans, ASH Ed. Book, 2010

take home message for clinicians-i

take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!!

take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!! 1- Patients should be counseled: disease-specific and treatment-specific risks for TR morbidity and mortality, acute and cgvhd, infectious complications, primary disease relapse, and late complications of transplantation.

take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!! 1- Patients should be counseled: disease-specific and treatment-specific risks for TR morbidity and mortality, acute and cgvhd, infectious complications, primary disease relapse, and late complications of transplantation. Information: Complications can result in worsened QoL.

take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!! 1- Patients should be counseled: disease-specific and treatment-specific risks for TR morbidity and mortality, acute and cgvhd, infectious complications, primary disease relapse, and late complications of transplantation. Information: Complications can result in worsened QoL. 2- GOOD NEWS: greater than 60% of transplant survivors report their QOL as good to excellent and greater than 60% have no major functional limitations.

take home message for clinicians-i Allogeneic HCT is an arduous treatment with curative potential that risks serious complications!!! 1- Patients should be counseled: disease-specific and treatment-specific risks for TR morbidity and mortality, acute and cgvhd, infectious complications, primary disease relapse, and late complications of transplantation. Information: Complications can result in worsened QoL. 2- GOOD NEWS: greater than 60% of transplant survivors report their QOL as good to excellent and greater than 60% have no major functional limitations. 3- BAD NEWS: following adverse outcomes: >25% of survivors will have ongoing significant medical problems and >25% experience emotional distress and impaired life satisfaction. Stated differently, at least 25% of survivors have ongoing bothersome symptoms.

take home message for clinicians-ii Blood. 2009;114:7-19

take home message for clinicians-ii Transplant physicians should consider performance as secondary to the curative potential of HCT, not underestimate patients symptoms, and overestimate their QoL and HR performance. Blood. 2009;114:7-19

take home message for clinicians-ii Transplant physicians should consider performance as secondary to the curative potential of HCT, not underestimate patients symptoms, and overestimate their QoL and HR performance. Increased awareness is needed regarding the impact of HCT on performance and the importance of QoL to patients. Blood. 2009;114:7-19

take home message for clinicians-ii Transplant physicians should consider performance as secondary to the curative potential of HCT, not underestimate patients symptoms, and overestimate their QoL and HR performance. Increased awareness is needed regarding the impact of HCT on performance and the importance of QoL to patients. Use update literature to help your patients to make informed decisions. Blood. 2009;114:7-19

Future Prospects

Future Prospects Long-term impact of resolved cgvhd

Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS

Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS Impact of RIC regimens,

Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS Impact of RIC regimens, Predictors of Functional health status after HCT

Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS Impact of RIC regimens, Predictors of Functional health status after HCT Establish a Cohort with collaboration of interested centers within EBMT

Future Prospects Long-term impact of resolved cgvhd Interventions to improve physical HS Impact of RIC regimens, Predictors of Functional health status after HCT Establish a Cohort with collaboration of interested centers within EBMT Performance of the team, physician???

KEY ISSUES To understand the contribution of pre-hsct exposures, HSCTrelated exposures and comorbidities in the development of adverse events. It is necessary to identify those at highest risk of complications. There is a need to develop intervention strategies. Long-term follow-up guidelines need to be disseminated and refined. Expert Rev. Hematol. 2011; 4: 437-54

KEY ISSUES To understand the contribution of pre-hsct exposures, HSCTrelated exposures and comorbidities in the development of adverse events. It is necessary to identify those at highest risk of complications. There is a need to develop intervention strategies. Long-term follow-up guidelines need to be disseminated and refined. Expert Rev. Hematol. 2011; 4: 437-54